What's Happening?
Pomerantz LLP has announced an investigation into Galectin Therapeutics Inc. on behalf of its investors. The investigation is focused on whether Galectin and its officers or directors have engaged in securities
fraud or other unlawful business practices. This follows a press release from Galectin on December 19, 2025, regarding the FDA's response to their Type C meeting request about the development program for belapectin, a galectin-3 inhibitor. The FDA's decision to convert the meeting request to a written response has left key aspects of the clinical trial design unresolved, leading to a significant drop in Galectin's stock price.
Why It's Important?
The investigation by Pomerantz LLP into Galectin Therapeutics highlights the potential legal and financial risks faced by companies in the pharmaceutical sector. Allegations of securities fraud can lead to significant financial losses for investors and damage to the company's reputation. This situation underscores the importance of transparency and compliance with regulatory requirements in clinical trial processes. The outcome of this investigation could have broader implications for investor confidence and regulatory scrutiny in the biotech industry.
What's Next?
Galectin Therapeutics is expected to pursue a follow-up Type C meeting with the FDA to address unresolved components of its clinical trial design. The outcome of this meeting will be crucial for the company's development program and investor relations. Meanwhile, Pomerantz LLP will continue its investigation, and affected investors may consider joining a class action lawsuit. The resolution of these issues will be closely watched by stakeholders in the pharmaceutical and investment communities.
